SEMAGLUTIDE 50MG

Description

Semaglutide 50mg research peptide — Canada

Researched & reviewed by the SPO Quality Team · Last reviewed: 2 October 2026

Semaglutide is a lipidated analogue of human GLP-1 developed by Novo Nordisk as a once-weekly GLP-1 receptor agonist; its discovery and development are reviewed in a 2019 paper^[1]. This listing is one sealed vial containing 50 mg of lyophilized research-grade semaglutide by label, the larger of our two strengths, supplied for laboratory research only.

Identity at a glance

Batch documentation: A batch-specific COA for this strength has not been posted yet — see the COA library (/coa/).

What researchers have looked at

• Development history (2019): a review from the originating group describes the albumin-binding fatty diacid and backbone changes that extended the half-life from liraglutide to semaglutide^[1].
• Head-to-head trial (2018): SUSTAIN 7, a 40-week phase 3b trial in type 2 diabetes, compared once-weekly semaglutide with dulaglutide on HbA_1c and body weight^[2].
• Oral formulation (2019): PIONEER 1 tested an oral tablet form of semaglutide against placebo over 26 weeks in type 2 diabetes^[3].
• Cardiovascular outcomes without diabetes (2023): the SELECT trial followed adults with overweight or obesity and established cardiovascular disease, with major adverse cardiovascular events as the primary endpoint^[4].

Regulatory status: semaglutide is licensed as Ozempic and Rybelsus (type 2 diabetes) and Wegovy (chronic weight management) in the USA, EU and elsewhere, with a 2016 cardiovascular-outcomes trial in its record^[5]; Health Canada lists all three as prescription drugs. Trial designs are listed to show where semaglutide has been studied; the results belong to Novo Nordisk’s licensed medicines and are not claims for this research material.

Storage and handling

• Long-term: −20 °C in the sealed vial (site guidance: up to 24 months as lyophilized powder). Short-term: cool, dry, away from light. Repeated freeze–thaw should be avoided.
• Solvents such as bacteriostatic water are listed separately; methods are set by the researcher.

Smaller vial: SEMAGLUTIDE 10MG. Dispatched by Canada Post within Canada (shipping policy); other compounds are listed on the page where you can buy peptides online in Canada.

Related reading: Semaglutide vs Liraglutide: How Acylation Changed GLP-1 Analogues

Frequently asked questions

Where can I buy semaglutide 50mg in Canada?

Here. The 50mg research vial is shipped by Canada Post from within Canada, so it does not pass through customs. It is sold for laboratory research only.

Has a COA been posted for the 50mg strength?

No batch-specific COA for the 50mg vial is in the COA library yet. We do not borrow the documentation of the 10mg vial or of any other product; this answer will change when a report is posted.

Why does a 50mg vial exist if the compound is the same?

The larger vial simply holds more labelled material, which some laboratories prefer for longer assay series. It is chemically the same semaglutide as the 10mg listing and is not described as better for any purpose.

Can this vial be used in place of Wegovy or Ozempic?

No. Wegovy, Ozempic and Rybelsus are Novo Nordisk’s licensed prescription medicines. This vial is unlicensed research material, and no dosing or administration guidance is provided.

Cited

1. Knudsen & Lau (2019), Frontiers in endocrinology — PMID 31031702
2. Pratley et al. (2018), The lancet. Diabetes & endocrinology — PMID 29397376
3. Aroda et al. (2019), Diabetes care — PMID 31186300
4. Lincoff et al. (2023), The New England journal of medicine — PMID 37952131
5. Marso et al. (2016), The New England journal of medicine — PMID 27633186

For laboratory research use only. Not for human or animal consumption. No dosing, administration or protocol information is provided, and nothing here is a claim of efficacy or safety in humans.